ºÐÀÚÀ¯ÀüÇнÇÇè½Ç (´Ü±¹´ëÇб³ ºÐÀÚ»ý¹°Çаú)
987
Àΰ£°ú »ýÁã À¯ÀüüÀÇ À¯»ç¼º°ú Â÷ÀÌÁ¡
À̼º¿í
2014/11/25
1989
986
Cost to Develop a Drug More Than Doubles to $2.56 Billion
À̼º¿í
2014/11/21
1186
985
¼¼±Õ°ú ½Î¿ìµµ·Ï ÀÚ±ØÇϸé, ¹ÙÀÌ·¯½º±îÁöµµ ¹°¸®Ä¡´Â ¼¼Æ÷
À̼º¿í
2014/11/20
1546
984
Gilead wins European approval of next-generation hepatitis C drug
À̼º¿í
2014/11/20
1197
983
[¹ÙÀÌ¿ÀÅäÇÈ] Ç¥ÁØ Àΰ£ °Ô³ðÁöµµÀÇ °¸À» ¸Þ¿ö¶ó: Ç÷¡Æ¼³Ñ °Ô³ðÁöµµ ź»ý
À̼º¿í
2014/11/19
1656
982
Á¾¾ç ³»¿¡¼ T ¼¼Æ÷ ¸é¿ª¿¡ ÇÙ½ÉÀûÀÎ Ç׿øÁ¦½Ã ¼¼Æ÷
À̼º¿í
2014/11/17
1748
981
AbbVie, Enanta drug shows potential in hep C genotype 4 patients
À̼º¿í
2014/11/15
1239
980
Gilead hepatitis C drug highly effective in cirrhosis patients
À̼º¿í
2014/11/14
1103
979
»õ·Î¿î HIV/AIDS Ä¡·á¹ý °³¹ß
À̼º¿í
2014/11/14
1502
978
°£ ÀÌ½Ä È¯ÀÚµéÀÇ CÇü °£¿°À» ¿ÏÄ¡½ÃŲ »õ·Î¿î Ä¡·á¹ý
À̼º¿í
2014/11/14
1715
977
°£ ÀÌ½Ä È¯ÀÚµéÀÇ CÇü °£¿°¿¡ È¿°úÀûÀÎ º´¿ë ¿ä¹ý
À̼º¿í
2014/11/13
1644
976
J&J Wins U.S. Approval for Hepatitis C Combo With Gilead
À̼º¿í
2014/11/07
1570
975
¿¡º¼¶ó¿¡ ´ëÇÑ ¹ÝÀÀ°ú À¯ÀüÀû ¿äÀÎ
À̼º¿í
2014/11/04
1321
974
½ÇÇè½Ç¿¡¼ ¸¸µç ÀΰøÀ§Àå
À̼º¿í
2014/11/04
1274
973
°Å¿ïÀ̹ÌÁö RNAÈ¿¼Ò¿Í »ý¸íÀÌ ±â¿ø
À̼º¿í
2014/11/03
1531
972
¾î¶»°Ô º¹ÀâÇÑ »ý¸íÀº ÁøÈÇߴ°¡?
À̼º¿í
2014/10/31
1642
971
Àΰ£ ³ì¾Æ¿ôÀ» ¿¬±¸ÇÏ´Â À¯ÀüÇÐÀÚµé
À̼º¿í
2014/10/31
1620
970
As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)
À̼º¿í
2014/10/31
1386
969
¾ÏÀÇ ¿ì±º-¿¢¼ÒÁ»(exosome)
À̼º¿í
2014/10/29
2837
968
ÀÌ¿ôÀÇ Á¤»ó¼¼Æ÷¸¦ °¨¿°½ÃŰ´Â ¾Ï¼¼Æ÷
À̼º¿í
2014/10/27
1512
[ÀÌÀü 10°³]
[1]
..
[11]
[12]
[13]
[14]
15
[16]
[17]
[18]
[19]
[20]
..
[64]
[´ÙÀ½ 10°³]
Copyright 1999-2023
Zeroboard
/ skin by
ROBIN